XORTX Therapeutics Inc. (XRTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
421 – 7th Avenue SW
Vancouver, BC T2P 4K9
Canada
Phone
+1 403 455 7727
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
September 23, 2021
| Name | Title | Pay | Year Born |
| Allen Warren Davidoff | Founder, Chief Executive Officer, President & Director | 324,738 | 1960 |
| Stephen Haworth MRCP | Chief Medical Officer | 96,000 | 1950 |
| Stacy Evans | Chief Business Officer | 150,000 | 1974 |
| Michael Scott Bumby | Chief Financial Officer | 160,980 | 1964 |
| David MacDonald | Consultant of Clinical Operations | 0 | 1963 |
| David Sans | Director of Corporate Development | 0 | 1970 |
| Charlotte May | Corporate Secretary | 0 | N/A |
| Nick Rigopulos | Director of Communications | 0 | N/A |
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.